A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Study Details
Study Description
Brief Summary
Evelo will investigate the safety and tolerability of EDP1066 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This will be a randomized, double-blind, placebo-controlled clinical study with dose escalations to assess safety, tolerability, and pharmacodynamic effect of EDP1066. Since this clinical study is the first study in humans, the participants will be healthy volunteers or subjects with mild to moderate psoriasis or atopic dermatitis who are otherwise well. Investigation of EDP1066 in this patient population provides an opportunity to gain pharmacodynamic information using a range of tissue biopsies and composite clinical endpoints.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Cohort 1 12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 66 mg, capsule, once daily, 15 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 2 12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 15 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 3 12 healthy volunteers; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 15 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 4 12 subjects with mild to moderate psoriasis; 8 on EDP1066, 4 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 5 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 6 up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 660 mg, capsule, once daily, 29 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 7 up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 8 up to 24 subjects with mild to moderate psoriasis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3g, capsule, once daily, 29 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
| Other: Cohort 9 up to 24 subjects with mild to moderate atopic dermatitis; 16 on EDP1066, 8 on placebo. Dose=up to a maximum of 3.3 g, capsule, once daily, 29 days |
Other: EDP1066
EDP1066 is an orally administered monoclonal microbial
Drug: Placebo oral capsule
placebo
|
Outcome Measures
Primary Outcome Measures
- Safety and tolerability measured through Adverse Events (AEs) [Day 1 to Day 60]
Number of participants with AEs by seriousness and relationship to treatment
- Safety and tolerability measured through lab measurements [Day 0 to Day 60]
Number of participants with clinically significant change from baseline (Day 0) in laboratory values
- Safety and tolerability measured through ECG [Day 0 to Day 60]
Number of participants with clinically relevant changes from baseline (Day 0) ECG parameters
- Safety and tolerability measured through physical examination [Day 1 to Day 60]
Physical examination of stool samples based on the Bristol Stool Scale (Types 3 and 4 are ideal stool): Type 1: Separate hard lumps, like nuts (hard to pass); Type 2: Sausage-shaped, but lumpy; Type 3: Like a sausage but with cracks on its surface; Type 4: Like a sausage or snake, smooth and soft; Type 5: Soft blobs with clear cut edges (easy to pass); Type 6: Fluffy pieces with ragged edges, a mushy stool; Type 7: Watery, no solid pieces, entirely liquid
- GI safety measurement through biomarker analysis [Day 1 to Day 60]
GI safety measurement through fecal calprotectin analysis
Secondary Outcome Measures
- Clinical improvement in subjects with mild to moderate psoriasis [Day 0 to Day 60]
Change from baseline (Day 0) Psoriasis-area-and-severity index score (PASI) in response to EDP1066, measured on a scale of 0 to 6 (where 0 is most favorable and 6 is least favorable).
- Clinical improvement in subjects with mild to moderate atopic dermatitis [Day 0 to Day 60]
Change from baseline (Day 0) Eczema-area-and-severity index score (EASI) in response to EDP1066, measured on a scale of 0 to 6 (where 0 is most favorable and 6 is least favorable).
Eligibility Criteria
Criteria
Inclusion Criteria:
General:
- Participant has a body mass index of ≥ 18 kg/m2 to ≤ 35 kg/m2 at Screening.
Healthy Volunteers:
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
Mild to moderate psoriasis:
-
Participant has had a confirmed diagnosis of mild to moderate plaque-type psoriasis for at least 6 months involving ≤ 5% of body surface area (BSA) (excluding the scalp).
-
Participant has a minimum of 2 psoriatic lesions with at least 1 plaque in a site suitable for biopsy.
Mild to moderate atopic dermatitis:
-
Mild to moderate atopic dermatitis with a minimum of 3% to a maximum of 15% BSA involvement.
-
Participant has had a confirmed diagnosis of mild to moderate atopic dermatitis for at least 6 months IGA score of 2 or 3.
-
Participant has a minimum of 2 atopic dermatitis lesions with at least 1 in a site suitable for biopsy.
Exclusion Criteria:
-
Female participant who is pregnant, or plans to become pregnant during the study, or breastfeeding, or sexually active with childbearing potential who is not using a medically accepted birth control method.
-
Participant has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study.
-
Participant has received any investigational drug or experimental procedure within 90 days or 5 half-lives, whichever is longer, prior to study intervention administration.
-
Participant requires treatment with an anti-inflammatory drug during the study period. Paracetamol will be permitted for use as an antipyretic and/or analgesic (maximum of 2 grams/day in any 24 hour period).
-
Participant has an active infection (e.g. sepsis, pneumonia, abscess) or has had an infection requiring antibiotic treatment within 6 weeks prior to Investigational Medicinal Product (IMP) administration. When in doubt, the investigator should confer with the Sponsor study physician.
-
Participant has renal or liver impairment, defined as:
- For healthy volunteers: i. For women, serum creatinine level ≥ 125 μmol/L; for men, ≥ 135 μmol/L, or ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 1.5 x upper limit of normal (ULN), or iii. Alkaline phosphatase (ALP) and/or bilirubin > 1.5 x ULN b. For participants with mild to moderate atopic dermatitis or psoriasis: i. For women, serum creatinine level ≥ 125 μmol/L; for men, ≥ 135 μmol/L, or ii. ALT or AST > 2 x ULN and/or bilirubin > 1.5 x ULN
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Surrey Clinical Research Center | Guildford | Surrey | United Kingdom | GU2 7XP |
| 2 | MAC Clinical Research | Barnsley | United Kingdom | S75 3DL | |
| 3 | MAC Clinical Research | Cannock | United Kingdom | WS11 0BN | |
| 4 | Royal Liverpool Clinical Research Unit | Liverpool | United Kingdom | L78XP | |
| 5 | MAC Clinical Research | Manchester | United Kingdom | M13 9NQ | |
| 6 | Medicines Evaluation Unit Ltd., The Langley Building, Wythenshawe Hospital | Manchester | United Kingdom | M23 9QZ | |
| 7 | MAC Clinical Research | Stockton-on-Tees | United Kingdom | TS17 6EW |
Sponsors and Collaborators
- Evelo Biosciences, Inc.
Investigators
- Study Director: Duncan McHale, MD, PhD, Evelo Biosciences
- Principal Investigator: Daryl Bendel, MBChB, MBA, University of Surrey
- Principal Investigator: Giuseppe Fiore, MD, Medicines Evaluation Unit Ltd
- Principal Investigator: Aliya Asher, MD, MAC Clinical Research
- Principal Investigator: Richard Fitzgerald, MD, Royal Liverpool Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EDP1066-001
- 2017-004337-90